|
Market Closed -
Saudi Arabian S.E.
13:20:00 01/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 62.20 SAR | -1.50% |
|
-3.12% | -2.11% |
| 09-17 | Avalon Pharma Renews SAR104 Million Bank Facility Deal with Banque Saudi Fransi | MT |
| 08-27 | Avalon Pharma Reiterated at Overweight as Aljazira Capital Notes 'Solid' Q2 Growth | MT |
Company Valuation: Middle East Pharmaceutical Industries Company
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 |
|---|---|---|
| Market Cap 1 | 2,436 | 2,224 |
| Change | - | -8.7% |
| Enterprise Value (EV) 1 | 2,479 | 2,253 |
| Change | - | -9.09% |
| P/E | 30.5x | 22.9x |
| PBR | 6.62x | 5.34x |
| PEG | 1.4x | 1.1x |
| Capitalization / Revenue | 6.18x | 4.83x |
| EV / Revenue | 6.29x | 4.89x |
| EV / EBITDA | 25x | 18.9x |
| EV / EBIT | 27.8x | 21.1x |
| EV / FCF | - | - |
| FCF Yield | - | - |
| Dividend per Share 2 | 1.143 | 1.383 |
| Rate of return | 1.64% | 2.18% |
| EPS 2 | 2.281 | 2.772 |
| Distribution rate | 50.1% | 49.9% |
| Net sales 1 | 394 | 460.5 |
| EBITDA 1 | 99.08 | 119.1 |
| EBIT 1 | 89.29 | 106.9 |
| Net income 1 | 79.85 | 97.01 |
| Net Debt 1 | 42.83 | 29.47 |
| Reference price 2 | 69.60 | 63.54 |
| Nbr of stocks (in thousands) | 35,000 | 35,000 |
| Announcement Date | 27/03/25 | 08/03/26 |
1SAR in Million2SAR
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 580M | |
| 32.45x | 11.78x | 23.93x | 0.61% | 1,019B | |
| 28.48x | 6.32x | 17.7x | 2.09% | 617B | |
| 33.26x | 7.78x | 16.08x | 2.64% | 464B | |
| 104.98x | 5.87x | 24.89x | 2.36% | 356B | |
| 18.81x | 4.58x | 11.36x | 2.9% | 333B | |
| 19.83x | 5.17x | 12.78x | 3.09% | 267B | |
| 20.02x | 4.17x | 11.86x | 2.13% | 244B | |
| 25.46x | 6.66x | 11.86x | 2.5% | 218B | |
| -43.78x | 6.39x | 24.97x | 2.27% | 179B | |
| Average | 26.61x | 6.52x | 17.27x | 2.29% | 369.78B | |
| Weighted average by Cap. | 31.80x | 7.61x | 18.61x | 1.96% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 4016 Stock
- Valuation Middle East Pharmaceutical Industries Company
Select your edition
All financial news and data tailored to specific country editions
